Man Group PLC Ngm Biopharmaceuticals Inc Transaction History

Man Group PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.31 $24,841 - $54,236	-41,402 Reduced 25.69%	119,740 $102,000
Q3 2023 Nov 14, 2023	BUY	$1.05 - $3.37 $68,624 - $220,253	65,357 Added 68.23%	161,142 $172,000
Q2 2023 Aug 14, 2023	SELL	$2.44 - $4.53 $126,887 - $235,573	-52,003 Reduced 35.19%	95,785 $248,000
Q1 2023 May 15, 2023	BUY	$3.72 - $5.4 $38,107 - $55,317	10,244 Added 7.45%	147,788 $602,000
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $344,560 - $1.31 Million	101,044 Added 276.83%	137,544 $690,000
Q3 2022 Nov 14, 2022	SELL	$12.59 - $17.67 $15,523 - $21,787	-1,233 Reduced 3.27%	36,500 $477,000
Q2 2022 Aug 15, 2022	BUY	$10.58 - $17.5 $168,571 - $278,827	15,933 Added 73.09%	37,733 $484,000
Q1 2022 May 16, 2022	BUY	$13.81 - $18.6 $98,051 - $132,060	7,100 Added 48.3%	21,800 $332,000
Q4 2021 Feb 14, 2022	BUY	$17.26 - $22.02 $18,986 - $24,222	1,100 Added 8.09%	14,700 $260,000
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $274,040 - $356,184	13,600 New	13,600 $286,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.